44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 18-21 March 2018, Lisbon, Portugal
Catalan Institute of Oncology, Barcelona, ES
- Dr Sureda gives a summary of the transplant algorithm in lymphoma highlighting that autologous stem cell transplant (ASCT) is still a standard of care in relapsed / refractory Hodgkin lymphoma.
- She explains that the results of ASCT have been improved by PET-adapted strategies. New drugs such as brentuximab vedotin and checkpoint inhibitors can improve disease status before transplant.
- Finally, she notes that allogeneic transplant is an option for those who relapse after ASCT but this will become less frequent as new drugs are more successful.